Endocyte Inc

Visual Financials
Company Name: Endocyte Inc
Ticker Symbol: ECYT
CIK Number: 0001235007
WWW Address: http://www.endocyte.com
CEO: Mr. Michael A. Sherman
No. of Employees: 76
Common Issue Type: CS
Business Description:Endocyte, Inc. is a biopharmaceutical Company. It targets therapies for the treatment of cancer and inflammatory diseases. It uses its proprietary technology to create novel small molecule drug conjugates, or SMDCs, and companion imaging diagnose.

 
Industry Information: DRUGS - Drug Manufacturers - Major [more like this]
 Price  Day Change  Bid  Ask  Open  High  Low  Volume 
 23.99 Unchanged 0.0 23.99 29.87  24.00 23.99 -
 Market Cap (mil) Shares Outstanding (mil) Beta EPS DPS P/E Yield 52-Wks-Range
 1,969.5 82.1 0.00 -1.25 0.00 0.0 0.0 24.00 - 2.81
KEY FIGURES (Latest Twelve Months - LTM)
Yesterday's Close23.99$
PE Ratio - LTM0.0
Market Capitalisation1,969.5mil
Latest Shares Outstanding82.1mil
Earnings pS (EPS)-1.25$
Dividend pS (DPS)0.00¢
Dividend Yield0.0%
Dividend Payout Ratio%
Revenue per Employee1,591$
Effective Tax Rate0.0%
Float76.9mil
Float as % of Shares Outstanding0.9%
Foreign Salesmil
Domestic Salesmil
Selling, General & Adm/tive (SG&A) as % of Revenue196.70%
Research & Devlopment (R&D) as % of Revenue369.50%
Gross Profit Margin0.0%
EBITDA Margin-55205.8%
Pre-Tax Profit Margin0.0%
Assets Turnover0.1%
Return on Assets (ROA)-45.1%
Return on Equity (ROE)-47.3%
Return on Capital Invested (ROCI)-47.3%
Current Ratio21.7
Leverage Ratio (Assets/Equity)1.1
Interest Cover
Total Debt/Equity (Gearing Ratio)
LT Debt/Total Capital0.0%
Working Capital pS1.15$
Cash pS0.00$
Book-Value pS4.23$
Tangible Book-Value pS1.16$
Cash Flow pS-0.66$
Free Cash Flow pS-0.67$
KEY FIGURES (LTM): Price info
Price/Book Ratio5.67
Price/Tangible Book Ratio0.00
Price/Cash Flow
Price/Free Cash Flow
P/E as % of Industry Group0.0%
P/E as % of Sector Segment0.0%
 
Balance Sheet (at a glance) in Millions
DIVIDEND INFO
Type of Payment-
Dividend Rate0.00
Current Dividend Yield0.0
5-Y Average Dividend Yield0.0
Payout Ratio0.0
5-Y Average Payout Ratio0.0
Share price performance previous 3 years

Share price performance intraday

 
PRICE/VOLUMEHighLowClose% Price Chg% Price Chg vs. Mkt.Avg. Daily VolTotal Vol
1 Week---0.61,982,86410,876,600
4 Weeks24.0023.3923.601.72,223,64842,249,319
13 Weeks24.0014.5017.5336.92,883,640181,669,369
26 Weeks24.0012.7613.7974.02,149,633270,853,878
52 Weeks24.002.814.25464.51,925,075481,268,967
YTD24.002.81-422.71,957,345479,549,692
Moving Average5-Days10-Days10-Weeks30-Weeks200-DaysBeta (60-Mnth)Beta (36-Mnth)
23.9523.9023.0018.4716.220.000.00
 
GROWTH RATES5-Year
Growh
R² of 5-Year Growth3-Year
Growth
Revenue-0.710.0-0.90
Income0.0
Dividend0.0
Capital SpendingNA
R&D0.00NA38.15
Normalized Inc.0.00NA0.00
 
CHANGESYTD vs.
Last YTD
Curr Qtr vs.
Qtr 1-Yr ago
Annual vs.
Last Annual
Revenue %0.00.018056.0
Earnings %0.00.00.0
EPS %0.00.00.0
EPS $0.160.160.92
 
SOLVENCY RATIOS
SHORT-TERM SOLVENCY RATIOS (LIQUIDITY)
Net Working Capital Ratio93.32
Current Ratio21.7
Quick Ratio (Acid Test)21.5
Liquidity Ratio (Cash)25.52
Receivables Turnover0.4
Average Collection Period900
Working Capital/Equity98.5
Working Capital pS1.36
Cash-Flow pS-0.77
Free Cash-Flow pS-1.06
FINANCIAL STRUCTURE RATIOS
Altman's Z-Score Ratio222.41
Financial Leverage Ratio (Assets/Equity)0.0
Debt Ratio0.0
Total Debt/Equity (Gearing Ratio)0.00
LT Debt/Equity0.00
LT Debt/Capital Invested0.8
LT Debt/Total Liabilities0.0
Interest Cover0.0
Interest/Capital Invested0.00
 
VALUATION RATIOS
MULTIPLES
PQ Ratio0.00
Tobin's Q Ratio19.55
Current P/E Ratio - LTM0.00
Enterprise Value (EV)/EBITDA-33.68
Enterprise Value (EV)/Free Cash Flow-39.85
Dividend Yield0.0
Price/Tangible Book Ratio - LTM0.00
Price/Book Ratio - LTM5.67
Price/Cash Flow Ratio
Price/Free Cash Flow Ratio - LTM
Price/Sales Ratio0.00
P/E Ratio (1 month ago) - LTM0.0
P/E Ratio (26 weeks ago) - LTM0.0
P/E Ratio (52 weeks ago) - LTM0.0
5-Y High P/E Ratio0.0
5-Y Low P/E Ratio0.0
5-Y Average P/E Ratio0.0
Current P/E Ratio as % of 5-Y Average P/E
P/E as % of Industry Group0.0
P/E as % of Sector Segment0.0
Current 12 Month Normalized P/E Ratio - LTM0.0
PER SHARE FIGURES
LT Debt pS0.00
Current Liabilities pS0.12
Tangible Book Value pS - LTM1.16
Book Value pS - LTM4.23
Capital Invested pS1.16
Cash pS - LTM0.00
Cash Flow pS - LTM-0.66
Free Cash Flow pS - LTM-0.67
Earnings pS (EPS)-1.25
 
OPERATING RATIOS
PROFITABILITY RATIOS
Free Cash Flow Margin-66,445.25
Free Cash Flow Margin 5YEAR AVG-32,724.43
Net Profit Margin-550.4
Net Profit Margin - 5YEAR AVRG.-400.7
Equity Productivity0.00
Return on Equity (ROE)-0.5
Return on Equity (ROE) - 5YEAR AVRG.-0.2
Capital Invested Productivity0.00
Return on Capital Invested (ROCI)-0.2
Return on Capital Invested (ROCI) - 5YEAR AVRG.-0.2
Assets Productivity0.00
Return on Assets (ROA)-0.5
Return on Assets (ROA) - 5YEAR AVRG.-0.2
Gross Profit Margin0.0
Gross Profit Margin - 5YEAR AVRG.
EBITDA Margin - LTM-55205.8
EBIT Margin - LTM-56523.9
Pre-Tax Profit Margin-400.7
Pre-Tax Profit Margin - 5YEAR AVRG.-400.7
Effective Tax Rate0.0
Effective Tax Rate - 5YEAR AVRG.0.0
EFFICIENCY RATIOS
Cash Conversion Cycle319
Revenue per Employee1,591
Net Income per Employee
Average Collection Period319
Receivables Turnover0.4
Day's Inventory Turnover Ratio
Inventory Turnover0.0
Inventory/Sales0.0
Accounts Payble/Sales537.71
Assets/Revenue0.00
Net Working Capital Turnover0.00
Fixed Assets Turnover0.03
Total Assets Turnover0.0
Revenue per $ Cash0.00
Revenue per $ Plant0.03
Revenue per $ Common Equity0.00
Revenue per $ Capital Invested0.00
Selling, General & Adm/tive (SG&A) as % of Revenue19671.2
SG&A Expense as % of Revenue - 5YEAR AVRG.0.0
Research & Devlopment (R&D) as % of Revenue36952.6
R&D Expense as % of Revenue - 5YEAR AVRG.36952.6

  
Your Recent History
NASDAQ
ECYT
Endocyte, ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:us D:20190619 04:43:30